SCHEMBL29890706

SCHEMBL29890706

COCCc1ccc2oc(C3CCN(c4c(C#N)c(=O)n(C)c5ccccc45)CC3)nc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 4/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ MCHR1 Q99705 1/20 0.34
▸ HTR4 Q13639 3/20 0.34
▸ THRB P10828 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ DGKZ Q13574 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ CTDSP1 Q9GZU7 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23410632 1.00 NPSR1 (0.36) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL23410722 0.94 NPSR1 (0.36) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL29890426 0.94 NPSR1 (0.36) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL23410817 0.87 LMNA (0.43) NPSR1THRBHSD17B10TP53LMNA
SCHEMBL29890575 0.87 LMNA (0.43) NPSR1THRBHSD17B10TP53LMNA
SCHEMBL23410934 0.86 HDAC6 (0.39) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL29890887 0.86 HDAC6 (0.39) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL29891463 0.86 TP53 (0.40) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL23410579 0.86 TP53 (0.40) NPSR1ALDH1A1USP2TSHRKMT2A
SCHEMBL23410738 0.85 MEN1 (0.40) NPSR1ALDH1A1USP2TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661869-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP claimed
EP-4661870-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP claimed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 — — CN claimed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 — — CN claimed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 — — CN claimed
WO-2024165470-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO claimed
WO-2024165469-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO claimed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP claimed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 — — CN claimed
EP-4661906-A1 COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
EP-4661870-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
EP-4661869-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 — — CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 — — CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 — — CN disclosed
WO-2024165470-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
WO-2024165468-A1 COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
WO-2024165469-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 — — CN disclosed
Send feedback